Philips leads a concentrated cardiac AI monitoring market
The Business Research Company says the cardiac AI monitoring and diagnostics market is fairly concentrated, with Philips leading global sales in 2024 and the top 10 players holding 35% of revenue. The report points to faster growth in AI-enabled ECG platforms, cloud monitoring and predictive tools as hospitals and device makers compete on clinical accuracy and workflow integration.
Why it matters: - Cardiac AI tools are moving deeper into diagnosis, monitoring, and treatment workflows. - The market’s concentration means a small group of companies can shape standards for clinical accuracy, interoperability, and regulatory compliance. - Early disease detection, faster clinical decisions, and remote monitoring are central to the market’s value proposition.
What happened: - The Business Research Company released its Cardiac AI Monitoring And Diagnostics Market Report 2026, covering market size, trends, and a global forecast for 2026-2035. - Koninklijke Philips N.V. led global sales in 2024 with a 6% market share. - The company’s cardiac monitoring and diagnostic solutions division includes cardiac monitoring systems, AI-enabled diagnostic imaging, wearable cardiac devices, and software platforms. - The report said the market is fairly concentrated, with the top 10 players accounting for 35% of total revenue in 2024. - The report listed major players including GE HealthCare Technologies Inc., Medtronic plc, Siemens Healthineers AG, Abbott Laboratories, iRhythm Technologies Inc., Boston Scientific Corporation, HeartFlow Inc., Canon Medical Systems Corporation, and Tempus Labs Inc.
The details: - Philips held the largest share at 6%, followed by GE HealthCare Technologies Inc. and Medtronic plc at 5% each. - Siemens Healthineers AG and Abbott Laboratories each held 4%. - iRhythm Technologies Inc. and Boston Scientific Corporation each held 3%. - HeartFlow Inc., Canon Medical Systems Corporation, and Tempus Labs Inc. each held 2%. - The report said market entry is shaped by clinical validation demands, global healthcare regulation, AI integration complexity, and the need for high accuracy and interoperability. - The report said major raw material suppliers include NVIDIA Corporation, Intel Corporation, Qualcomm Incorporated, IBM Corporation, Amazon Web Services Inc., and several healthcare and technology firms. - Major wholesalers and distributors include McKesson Corporation, Cardinal Health Inc., AmerisourceBergen Corporation, Medline Industries LP, and Owens and Minor Inc. - Major end users include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Mount Sinai Health System, Stanford Health Care, Kaiser Permanente, Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, Narayana Health, and the National Health Service United Kingdom.
Between the lines: - The market favors firms that can pair validated algorithms with existing hospital systems. - That helps explain why larger device makers and AI-focused startups are competing in the same space. - The report said AI-enabled ECG interpretation platforms are reshaping the market by improving early detection, diagnostic accuracy, and clinical speed. - In July 2025, Royal Philips launched the Philips ECG-AI marketplace to centralize access to AI-powered cardiac diagnostic tools. - The platform integrates validated third-party algorithms into existing ECG systems, reducing integration complexity across healthcare workflows.
What’s next: - Companies are pushing deeper into deep learning for ECG analysis and arrhythmia detection. - More vendors are integrating AI-powered echocardiography and cardiac MRI interpretation tools. - Cloud-based remote monitoring and risk prediction platforms are expanding. - Real-time AI analysis for wearable cardiac devices is becoming a key competitive strategy. - The report expects strategic collaborations, product innovation, and regional expansion to strengthen leading players’ positions.
The bottom line: - Cardiac AI monitoring is becoming a scale-and-validation market, not just a software race. - Winners will likely be the companies that can combine accurate algorithms, clinical trust, and easy integration into hospital workflows.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Massachusetts Business Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.